Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China

MT Newswires Live2025-04-04

Sino Biopharmaceutical's (HKG:1177) TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.

The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.

ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.

Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.

The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2524273305?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-04 15:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524273305","market":"sg","top_or_hot":-1,"title":"Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China","media":"MT Newswires Live","content":"<html><body><p> Sino Biopharmaceutical's (HKG:1177) TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.</p><p>The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.</p><p>ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.</p><p>Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.</p><p>The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-04 15:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Sino Biopharmaceutical's (HKG:1177) TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.</p><p>The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.</p><p>ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.</p><p>Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.</p><p>The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524273305","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524273305","pubTimestamp":1743750574,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sino Biopharmaceutical's  TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1515":"抗疫概念","01177":"中国生物制药","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药"},"translate_title":"中国生物制药抗肿瘤药物获中国默示批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"Sino Biopharmaceutical's (HKG:1177) TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2524273305","isCrawlerRequest":true}